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Congestive heart failure is a type of cardiovascular disease that is often accompanied by 
excess fluid buildup in tissue, causing swelling of the extremities, known as peripheral edema. 
Assessing the severity level of pitting, or indentation, in peripheral edema can potentially 
provide insights about one’s heart condition. When clinicians use digital manipulation to assess 
severity, the measurements are subjective. Objectifying measurements requires standardization 
so the severity score reported is both reliable and consistent across providers. 
The HeartSMART system was developed to calculate the level of peripheral edema via 
four factors: the depth (displacement) of the skin, the force exerted on the skin, the surface 
temperature of the skin, and body weight. The specific aim of this project was to begin the 
process for developing an algorithm that could provide an overall standardized edema score 
based on these four parameters obtained from the HeartSMART system. Using the recorded 
force and displacement measurements from participants with varying levels of edema, we fit the 
collected data to a derivation of the standard linear sold model in order to establish edematous 
tissue properties. Additionally through clinical testing, we identified improvement opportunities 
to the device design to make it more user friendly.   
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CHAPTER 1:  INTRODUCTION 
Cardiovascular Disease (CVD) is a condition that impacts the heart and blood vessels. 
CVD is the leading cause of death globally and, with stroke, CVD creates massive health and 
economic burdens [1]. According to AHA 43.9% of the US population is projected to have some 
form of CVD by 2030. AHA also projects that between 2012 and 2030 the direct medical costs 
of CVD will increase from $396 billion to $918 billion [2]. Americans die from CVD an average 
of 1 death every 40 seconds [3]. However, studies reveal that CVD can be reduced or prevented 
by decreasing risk factors such as high blood pressure and lack of exercise [4,5].  The 2020 
Impact Goal of the American Heart Association states, “By 2020, [the goal is] to improve the 
cardiovascular health of all Americans by 20%, while reducing deaths from cardiovascular 
diseases and stroke by 20%” [2]. This goal introduces a new concept known as ideal 
cardiovascular health that includes four health behaviors (cessation from smoking, increased 
physical activity, healthy diet, and healthy body weight) and three health factors (cholesterol, 
blood pressure, and blood glucose). While medications are definitely important for managing 
CVD, dietary and lifestyle changes are necessary and recommended to all patients [2]. 
One type of CVD is congestive heart failure (CHF), during which the pumping action of 
the heart becomes compromised [6] and blood cannot maintain proper flow through the body. 
Consequently, blood builds up and increases pressure in the vessels, causing fluid to leak into 
body tissues. This excess fluid results in tissue swelling (edema) of the extremities [3,7]. 
Worldwide there are over 20 million people with CHF. Approximately 5.7 million Americans 
live with CHF according to the American Heart Association’s 2015 Statistical Report. On a 
yearly basis there is estimated to be 660,000 new cases of CHF and a mortality rate of 287,000 
people. Upon diagnosis, half of CHF patients die within 5 years. Each year, there are 11 million 
physician visits focused on heart failure. When compared with the total of all forms of 
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cancer, heart failure results in greatest number of hospitalizations [2]. There is evidence that 
CHF can be managed with clinical intervention and self-care. Cardiac rehabilitation programs 
encourage CHF obese patients to lose weight through diet and exercise and CHF stable patients 
to participate in moderate aerobic exercise. Even with such changes, patients need to be 
motivated to provide self-care [3].  
One indicator of CHF is peripheral edema, which is swelling in the soft tissues 
caused by an increase of the interstitial volume. The dynamics that result in this increase in 
volume are due to physiological processes in the heart and kidneys. Atrial-renal reflexes 
maintain total body volume in the normal range. Under normal conditions, an increase in 
atrial pressure prevents arginine vasopressin (AVP) release, decreases renal sympathetic 
tone, and promotes natriuretic peptides (ANP and BNP) release, all of which increase renal 
sodium and water excretion. However, in HF these normal reflexes are diminished due to the 
phenomenon of underfilling of the heart, during which blood backs up in the venous system 
and the effective arterial volume is decreased because of decreased cardiac output. Arterial 
volume receptors sense this attenuation in arterial filling (i.e. effective arterial volume) and 
trigger sympathetic nerve-mediated vasoconstriction of systemic and intrarenal arterioles in 
order to reestablish a normal ratio of cardiac output to vascular resistance. In addition, the 
impeding effects of the arterial stretch baroreceptors on the neurohumoral systems (such as 
AVP release) are lessened, increasing sodium reabsorption and AVP mediated water 
retention [8].  
Because the presence of edema in the lower extremities is a useful diagnostic marker 
for the acuteness of the disease, the progression of CHF can be monitored over time with the 
progression of the severity level of edematous tissue.  Changes in these patient conditions 
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are useful indicators to determine further intervention [9]. Even though edema is often a 
symptom of a more serious medical condition, the assessment process is only one indicator 
of a patient’s condition and presence of peripheral edema may not always be a primary 
concern for the clinician.  It is of significance to note that more patients are hospitalized for 
CHF due to increased fluid retention rather than severe breathlessness. Patients with greater 
levels of edema have more renal dysfunction and anemia and are more likely to have right 
heart failure [10].  
The traditional standard for predicting imminent heart failure and preventing 
repeated hospitalization is fluid monitoring through edema assessment and daily weight 
[11]. Clinicians assess the level of edema by the amount of “pitting”, or indentation, in the 
skin, as shown in Figure 1 [12], as well as the time in seconds for skin rebound. Clinicians 
assign a value between 1+ and 4+, inclusive, 
based on their experience and observation. The 
major issue with this digit press test to diagnose 
edema severity level is the subjective nature of the 
process. A cause for concern is that repeated 
measurements by different clinicians may be 
inconsistent. Some clinicians rely on rebound time to determine the score while others focus 
primarily on depth of indentation. In spite of these concerns, digital manipulation remains 
the gold standard. Devices currently available to assess pitting edema remain expensive, 
unwieldly, or inaccurate [13]. Advancements in improved monitoring of such measurements, 
especially for in-home use, can improve patient outcomes and quality of life when dealing 
with chronic illnesses [14,15]. 
Figure 1. Levels of pitting edema [12]. 
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This thesis project focuses on design of an in-home monitoring system that can 
objectively measure peripheral edema. Furthermore, the system incorporates a standard 
linear solid (SLS) algorithm based on a viscoelastic tissue model. In this study, we have 
recorded force and displacement measurements from patients with varying levels of edema 
then fit this data to a SLS model in order to establish edematous tissue properties. The thesis 
contributes to biomedical engineering by providing a framework in which to determine the 
viscoelastic constants for peripheral tissue at differing levels of edema severity. Referencing 
the framework will allow a process for reducing subjectivity and thereby establishing a 
standardized measurement procedure for the severity of peripheral edema. 
This thesis is organized into the following chapters. Chapter 2 summarizes a review 
of the literature of engineered peripheral edema measuring devices. Chapter 3 presents a 
detailed description of the HeartSMART system design and a preliminary validation study 
using foam. Chapter 4 provides an explanation for the application of a soft tissue model to 
edematous tissue and the hypothesis for the study. Chapter 5 describes the experimental 
methods for clinical data collection. Chapter 6 presents the results. Chapter 7 discusses the 
data analyses, improvement opportunities, and future direction for the HeartSMART system. 
Chapter 8 states the conclusions from the study.  
  
  
 
 
CHAPTER 2:  BACKGROUND 
2.1 From Hospital to Home Care 
Preventing and managing serious conditions such as obesity, diabetes, and heart disease 
are challenges for health care providers. With innovations in technology, opportunities exist for 
enhanced communication and prevention measures made possible through digital design and 
advancement [16,17]. In addition to improving (1) treatment and diagnosis, (2) communication, 
and (3) data retrieval with the use of mobile devices and apps, these same devices are a solution 
for self-care management. Rising healthcare costs are an additional incentive for self-care. In the 
U.S. healthcare spending has increased from 75 billion in 1970 to 2.6 trillion in 2010. It is 
predicted to reach 4.8 trillion in 2021 [18].  
Heart failure is the top discharge diagnosis, accounting for 32 billion health care dollars 
[19]. The amount will only increase due to longevity and increasing survival rates of once deadly 
heart attacks. Because the finances are so monumental, healthcare providers are seeking better 
ways to enable patients to participate in their own self-care to lower health care costs [5]. 
Patients are being encouraged to accept more responsibility for their health in order to eliminate 
or shorten their hospital stays [20].  Due to the availability of improved treatment options and an 
increased awareness by the public of the benefits of healthy lifestyles, there are indications that 
hospitalization rates for chronic illnesses could decrease.  
As the health care system continues to reward better health outcomes, mobile devices and 
apps can support this goal [14,21,22,23,24,25]. Studies provide evidence that patient care 
outcomes are impacted positively by mobile devices, such as reduced length of hospital stay [14, 
23]. The healthcare system is now poised to enable individuals to participate in their own care 
(self-care). This shift in paradigm from reactive care to proactive and preventative care will 
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require devices adapted for home use as well as improved patient education. BlueCross 
BlueShield of North Carolina is now offering monetary incentives for participation in “My 
Active Health” and “Self-Assessments” [26]. Moving from clinic centered care to patient 
centered care means extending healthcare to the home and community [27]. 
There are a variety of patents and research studies published about digital devices that are 
used for the detection and management of cardiac associated diseases where edema is a symptom 
[13]; however, only the indentation (digital manipulation) method is included in standard clinical 
practice. Although “measuring internal properties of tissue, such as the water content, 
impedance, thermal energy or ultrasound or magnetic resonance imaging of the tissue 
provides accurate, quantitative representations of edema severity in tissue,” [13, p.9] these 
methods are “too expensive and unwieldy for using on a regular basis to assess edema” [13, 
p.10]. Other methods entail circumference measurements [28], water displacement [28], and 
impedance measurements [29].  However, these methods would not be considered for patient use 
at-home due to patients’ lack of training and ability to perform the tests on their own, which 
would be a requirement for an at-home device. Another published device, similar to the 
prototype investigated in this study, is a hand held version [13], which patients would not be able 
by themselves to maneuver successfully against their leg.  
Investigations continue for the purpose of designing more affordable measurement 
devices [13], especially those compatible with home use, since in-home health care is predicted 
to improve the quality of care and reduction of healthcare costs. Proactive and preventative 
measures [27] will necessitate the development of equipment, procedures, and training that 
support patient-centered care [30].  For example, patients will need to acquire specific skills for 
following detailed instructions to assess the presence of edema as an indicator of their heart 
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failure disease, much like reading a thermometer to detect presence of a fever as a symptom of 
disease.   
2.2 Significance 
A daily monitoring system that would objectively monitor both weight and level of 
severity of edema to produce a consistent overall edema score would be an asset. The system 
would be wireless so health care professionals could continuously observe their patients from a 
remote location as well as provide patient feedback. The HeartSMART system is a vital tool that 
can be used by health care professionals to monitor heart failure progression and patients to 
improve their self-management skills. Continual use of this system will help individuals 
recognize how significant weight control and fluid monitoring is to their overall health and 
prevention of worsening conditions. Because the system is mobile and will be wireless, patients 
can use the device in their home while providers can monitor from a remote location. 
Information about disease management would be provided during the hospital stay to assist in 
preventing re-admittance in a health care facility, especially within 30 days of the last visit.   
2.3 Previous Research 
Reliable Methods for Assessing Peripheral Edema  
Healthcare professionals use a variety of methods to gather data to assist in assessing the 
severity of edema. In 2009 Brodovicz et al. sought to compare the reliability of these 
measurements and the degree of correlation with the traditional clinical assessment of pitting 
depth and recovery. The methods were evaluated with 20 patients exhibiting a range of edema 
severity. Methods included patient questionnaire, ankle circumference, figure-of-eight (ankle 
circumference using eight ankle/foot landmarks), edema tester (plastic card with holes of varying 
size pressed to the ankle with a blood pressure cuff), modified edema tester (edema tester with 
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bumps), indirect leg volume (by series of ankle/leg circumferences), and foot/ankle volumetry by 
water displacement [31]. 
The investigation found that water displacement and ankle circumference had high inter-
examiner agreement; however, drawbacks of water displacement methods include time required 
and implementation challenges. The subjective traditional assessment by nurse-performed 
assessments was correlated with the patient questionnaire, which suggests a questionnaire is a 
reliable and accurate method of assessing edema [31]. 
Devices that measure peripheral edema by probe depression measurements 
A variety of devices have been patented to provide a reliable, accurate and quantifiable 
measure of a patient's edema that is user-independent by using probes that record displacement. 
The devices have been used to successfully collect measurements, but sample sizes were small. 
Other limitations included the variation in positioning and rate of application of force of the 
probe by different users [12] [US Patent #8425433:2008] [U S Patent# 6186962B1: 2001]. 
Devices that measure peripheral edema by tape measuring device 
Those prototypes using an optical encoder, combined with a microprocessor and LCD, 
produced reliable and accurate measurements; however, limitations were the functionality of the 
internal assembly, the clip mechanism, and the power spring configuration [32]. 
When comparing spring tape and optoelectronic volumetry to measure leg and ankle 
circumference, advantages of the spring tape was the inexpensive cost and ease of use, but there 
was high user variance. The volumeter was the preferred choice. The study was limited in that 
the same investigator performed all measurements so inter-rater variability was not assessed. In 
addition, the study only tested healthy volunteers rather than patients experiencing limb swelling 
[33].  
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Another study investigating the delta in limb volume changes based on tape-measure 
measurements of limb circumference (girth) produced reliable results when girth measurements 
were completed with consistent tension and limb position and measurement sites were 
standardized [34]. 
Devices that measure peripheral edema by water displacement 
A lower extremity is placed into a container filled with a displaceable medium, resulting 
in the displacement of a portion of the displaceable medium. The amount of the displaced 
portion is then determined and related to the volume of the lower extremity in the container. 
From the measured volume, the presence or absence of edema is determined. The measurement 
may be repeated to measure the progression of the edema [US Patent#6077222: 2000]. 
Devices that measure peripheral edema using a ratio of the extra-cellular to intra-cellular fluid 
This device measures impedance for first and second body segments. An index for each 
body segment is calculated that is a ratio of the extra-cellular to intra-cellular fluid. The index 
ratio is used to determine the presence, absence or degree of tissue edema. A comparison is 
made with the index ratio of a reference [US Patent#8744564 B2: 2005]. 
Devices that measure peripheral edema by volume sensing 
The perimeter of a peripheral extremity, like an ankle, is measured to obtain a perimeter 
value. The perimeter value is then compared to a control value and any difference is identified. 
The difference is then related to the presence of edema in the patient [13].  
 As an example of a commercial product based on this concept is the Perometer that 
ranges in cost from $15,000 to $30,000, a price that is too expensive for most hospitals. The 
patient must be mobile to sit or stand in the sensing area, thus only certain patients would 
benefit. The device scans the limb with infrared sensing and calculates limb volume. 
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Advantages are ease of use, no clean up, fast, view segments of a limb [US Patent#5891059 A: 
1999]. 
Devices that measure peripheral edema by impedance measurement 
The device measures bioelectrical impedance at a single frequency. Comparing the 
measurement recorded for the tissue compared with tissue unaffected by edema [US 
Patent#8233974 B2: 2004]. 
This device provides an impedance measurement, passing a high frequency current through the 
affected tissue via electrodes. It has a more limited patient compliance than other more 
simplistic methods [US Patent# 6714813: 2004].  
Devices that measure peripheral edema by modeling relationships between tissue water 
content and thermal property of tissue 
The device models the relationship between tissue water content and a thermal property 
of tissue that varies as a function of tissue water content. A thermal probe is placed in contact 
with tissue at a selected site and is energized to transfer thermal energy to the tissue. Tissue 
water content is calculated as a thermal property of tissue, which varies as a function of tissue 
water content. Edema is quantified as a function of the power used to heat tissue at a selected 
site and the thermal conductivity of tissue. For example, thermal diffusivity and thermal 
conductivity of the tissue increase as the water content of the tissue increases. The thermal 
response to the introduction of heat in a selected tissue sample or organ is a function of these 
properties [US Patent# 6488677: 2002]. 
Devices that measure peripheral edema by 3D imaging 
Five healthy subjects participated in a study using low-cost sensors for leg edema 
detection as a method for home monitoring to prevent or reduce re-hospitalization. 3D camera-
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based images were correlated with body weight and leg circumference to detect and quantify leg 
edemas. The results suggest further investigation [35]. 
Devices that measure inhomogeneous soft tissues in patients with peripheral edema  
A hand held stiffness meter was designed to evaluate factors that affect 
indentation responses of inhomogeneous soft tissues (skin, adipose tissue, muscle) on 
the experimental indentation responses recorded by the stiffness meter.   
The study suggested that a 3D model, instead of the present 2D model, is needed for a more 
realistic simulation of the soft tissue behavior under indentation. The 3D model may be created 
by using MR or CT imaging [28] [US Patent # 8,147,428: 2005]. 
Devices that measure foot edema by dielectric electro-active polymer sensors 
For continuously monitoring foot edema, this model showed that DEAP (dielectric-
electro-active polymer) sensors are suitable for use in wearable monitoring systems. They allow 
for very limited pressure on the foot, which allows for valid measurements. Because the sensing 
values follow the same pattern during pump-in/pump-out phase, but shift on both amplitude and 
phase, measurements were reported as reliable. Future work should consider designing an 
advanced data analyzing algorithm with a suitable calibration of each measurement [36]. 
Impact of monitoring systems and response training 
A heart failure (HF) training program (SMART- for symptom monitoring and response to 
decrease uncertainty surrounding the meaning of symptoms experienced) was investigated for 
increase in patients’ ability to recognize and respond to changes in HF symptoms. Participants 
received weight scales and a HF self-care booklet written at the 6th to 8th grade. Intervention 
participants received 4 additional education modules. The training appeared to have an early but 
not sustained benefit, which meant no difference in 90-day event-free survival between groups. 
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Improvement in self-care maintenance and confidence scores in the intervention group was 
greater but not significant. Effective self-care, with daily symptom monitoring and 
knowledgeable decision-making about symptoms appears to help patients with HF maintain an 
acceptable quality of life and avoid repetitive hospitalizations [37].  
  No differences in hospitalization rates were reported between control and treatment 
groups that experienced heart failure program care versus heart failure program care plus the 
AlereNet system (Alere Medical, Reno, Nevada). There was a 56.2% reduction in mortality for 
patients randomized to the AlereNet group, even though both groups received specialized and 
aggressive heart failure care. The intervention appeared to improve survival rates [38]. 
In a third study no differences were reported between the treatment (usual care plus a 
medication compliance device linked to a Web-based monitoring system) and control (usual 
care only). At baseline and 3 months, there were no differences reported between groups 
as to self-care behaviors, pill counts, 6-minute walk-test distance, or Functional Class. Yet, 
quality of life improved significantly for the treatment group. Patients in the compliance 
device group had 94% compliance with taking medication, 81% compliance with daily blood 
pressure monitoring, and 85% compliance with daily weight monitoring compared to 51% 
and 79% for blood pressure and weight monitoring, respectively, in the control group [39].  
Conclusion 
The review indicates that there is no one preferred device to measure severity levels of 
peripheral edema.  Limitations of the studies included small sample sizes, using only healthy 
participants, lack of testing by more than one user, and challenges in use of method or device. In 
this thesis study a total of 30 healthy and CHF subjects exhibiting different levels of edema were 
tested. In addition, prior to subject testing, the force and displacement sensors were validated 
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with foam testing to determine baseline measurements of force and displacement as they 
correlate to the simulated level of edema. Healthcare providers continue to use the method of 
indentation with their hands which results in a subjective scoring and a lack of reliability 
between providers as to the degree of peripheral edema in patients. The development of a 
standardized method will enhance the continuity of care and increase the ability of providers to 
predict exacerbations of heart failure.  
  
 
 
CHAPTER 3: DEVICE DESIGN AND FUNCTION 
3.1 Design Overview 
An illustration of the HeartSMART system components is shown in Figure 2. Our device 
utilizes mechanical and electrical components that can provide more accurate and repeatable 
measurements compared to the current digit press test executed in the clinic.  
3.2 Mechanical Components 
The mechanical components include a base, indentation device, adjustable shin rest, and 
lever arm. The base, which is constructed from acrylic sheets, provides housing for the weight 
scale and structure for the other components.  The base is large enough to allow the subject to  
 
Figure 2. HeartSMART system components; A) Overall design, B) zoom-in on the indentation method, 
and C) a zoom-in on the indenter. 
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stand for weight measurement and sit for edema measurement. The indentation device consists of 
the indenter that slides over a support attached to a shin guard. The shin guard can be adjusted to 
account for variations in subject heights. A displacement sensor is housed inside the support and a 
force sensor is attached to the end of the indenter. The original housing design is captured in a 
sketch shown in Appendix A. The indenter, support and shin guard were designed in SolidWorks 
and later 3D printed. The lever arm is used to push the indentation device into the subject’s leg. 
3.3 Electrical Components 
The displacement sensor chosen is the Subminiature Gauging DVRT, as shown in Figure 3. 
The Subminiature Gauging DVRT® consists of a ruby bearing and hardened stainless steel ball that 
guide the spring-loaded tip. The sensor 
exhibits sub-micron resolution, linear analog 
output, and ease of use. This displacement 
sensor can measure up to 10 mm, which is 
above the expected maximum displacement of 8mm for a level 4+ edema patient. The force sensor 
chosen is the Honeywell FS101 Pressure Sensor, as shown in Figure 4. It is a peizoresistive-based 
force sensor that provides an accurate and stable output over an 
operating range of 0 to 1.5 pounds, with a maximum force of 7 
pounds. The sensor was chosen because of its small size, low cost, 
and low noise. One of its common applications is load and compression sensing. 
The displacement and force sensors are connected to a National Instruments Elvis II+ circuit 
board. The circuit board is connected to a Dell laptop with LabView Software, as shown in Figure 
 
Figure 3. Displacement sensor, SG-DVRT-8-SK1. 
 
 
Figure 4. Fore sensor, FS01. 
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5. Voltage readings from the displacement sensor are converted into displacement readings in 
millimeters and voltage readings 
from the force sensor are 
converted into force readings in 
pounds. Data collected is stored as 
Microsoft Excel files for further 
analysis. 
The Withings wireless weight scale is an electronic blue-tooth enabled scale that records 
subject weight. The Exergen Temporal Scanner Infrared Thermometer is a separate component used 
to collect patient skin temperature on the forehead and leg.  
3.4 Mobile Application Development 
Concurrently, development of a mobile application (app) is in progress. The app will collect, 
analyze, and store data from the displacement and force sensors and the weight scale in order to 
determine severity levels of edema A Sparkfun IOIO-OTG circuit board, as shown in Figure 6, will 
replace the NI Elvis II+ circuit board, the designed app will replace the LabView software, and the 
2013 Nexus 7 tablet will replace the laptop. The 
Sparkfun IOIO board connects with the Android 
operating system KitKat 4.4.4 through a USB or 
Bluetooth connection and can be controlled by an 
Android app via Java programming language API 
(application programming interfaces). The IOIO 
board has one MCU (micro controller unit) that serves as a USB host and deciphers commands 
from the app. The IOIO board can be used with Digital Input/Output, PWM, Analog Input, I2C, 
SPI, and UART control. The IOIO board can be used with the V3.04 bootloader, which interfaces 
 
Figure 6:  IOIO-OTG circuit board. 
 
Figure 5. NI Elvis II+ circuit board and laptop with LabView 
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with Android devices over a Bluetooth connection via an USB Bluetooth dongle attached to the 
board.  
3.5 Foam Study 
 The main purpose of the foam study was to validate the force and displacement sensors 
with foam sample testing to determine baseline measurements of force and displacement as they 
correlate to the simulated level of edema. Foam samples consisting 
of high-density memory foam were tested on the HeartSMART 
system. Squares of foam were cut to different thicknesses and soaked 
in vegetable oil. The varying thicknesses were representative of the 
different levels of edema. Vegetable oil was used as the most 
representative liquid for soft 
tissue models. Dr. Sonya 
Hardin, an edema specialist, verified that the samples did 
indeed represent the different levels of edema. Table 1 
illustrates the foam thickness associated with each edema 
level. The setup for testing is shown in Figure 7. A lower leg 
model consisting of a cylindrical PVC pipe stabilized with 
concrete in a foil pan was used to hold each piece of foam in the shin guard. Each foam sample was 
tested on the device three times. The detailed testing protocol is described in Appendix B.  
Results showed that as the simulated level of edema increased (i.e. the foam thickness 
increased), the depth of 
indentation increased. Table 2 
illustrates the collected data. It is 
important to note that the 
Table 1. Edema correlation 
to foam thickness 
Edema 
Level 
Foam 
Thickness 
Sample # 
None 0.25” 1 
1+ 0.50” 2 
2+ 0.75” 3 
3+ 1.00” 4 
4+ 1.25” 5 
 
Table 2. Foam testing results 
Foam Thickness 0.25" 0.50" 0.75" 1.00" 1.25" 
Average Maximum Displacement (mm) 1.774 4.470 9.751 9.752 9.751 
Standard Deviation (mm) 0.077 0.325 0.001 0.001 0.001 
Average Force (lb) 5.093 4.900 4.317 4.453 4.743 
 
 
Figure 7. Foam testing setup 
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maximum displacement of the sensor 
(9.75 mm) was reached for the 0.75 inch, 
1.00 inch and 1.25 inch thick sections of 
foam. Because the pitting seen in the 
severest cases of edematous tissue in 
human subjects is 8 mm, it is expected 
that maximum displacement of the 
sensor will not be reached during patient 
testing. Figure 8 represents the force and 
displacement data for the first models. 
As level of edema increases the 
displacement due to the approximately same amount of force increases. The relationship between 
the force and displacement was investigated by applying a trend line to the force application portion 
of the curve, as shown in Figure 9. The test results demonstrate that the device works well and is 
ready for data collection on human subjects.  
 
Figure 8. Displacement and force data for samples 1-3 
Figure 9:  Force vs displacement curves for samples 1-3 
  
 
 
CHAPTER 4: EDEMA CLASSIFICATION USING SLS TISSUE MODEL 
4.1 Application of the Standard Linear Solid (SLS) Model 
Bone and soft tissues, including blood vessels, nerves, muscle, fat, and skin, have 
viscoelastic properties. In addition, edematous tissue exhibits viscoelastic characteristics. One 
property of viscoelastic materials is that they enable large deformations [40]. This property is the 
basis for edema measurements recorded by healthcare providers; however, as previously stated, 
visual diagnosis alone results in high intra- and inter-provider variability. For the purpose of 
eliminating the need for multiple sensors and to obtain objective measurements of edema levels, 
a material model can be developed to examine creep (which is increased deformation under a 
constant applied load), dependence on rate of loading, and dependence on history of force 
application [40]. Maintaining these measurements across providers and across multiple 
measurements will maintain consistency in readings for the purpose of improving diagnosis and 
treatment [13].  
A simple model of soft tissue can be represented by its resistive property, i.e. the 
mechanical resistance R. Resistance can be calculated as shown in equation 1,  
𝑅 =
𝑃
𝑣
                                                                                                                     (1), 
where P is the pressure applied to the surface of the tissue and v is the velocity (i.e. the rate of 
change of displacement of the tissue). Excess interstitial fluid buildup in edematous tissue 
changes the properties of the tissue. 
More sophisticated models contain multiple components.  The elastic response can be 
modeled with linear springs En and the viscous characteristic can be modeled with dampers ηn. 
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Figure 10 illustrates several configurations for soft tissue modeling. Fitting collected 
experimental data from the sensors to a model allows for determination of edematous tissue  
properties thereby providing alternative measures for edema [41]. 
Based on the design of the HeartSMART system, the standard linear solid (SLS) model 
was best suited to determine edematous tissue properties. Fitting the experimental data to this 
model was the first step in developing an algorithm that could provide an overall standardized 
edema score for each user. One assumption of the model is that the stress applied to the tissue 
is constant. However, in this study, the applied stress was not constant. Therefore, the model 
must be modified to account for changing stress. Appendix C provides the derivation to the 
solution for creep when the stress applied to the tissue is not constant. The final equation used 
in the data analysis is shown in equation 2, where ε is the strain, a1 is the slope of the force 
over time, t is time, u(t) is the unit step function, η1 is the damping coefficient, and E1 and E2 
are the two spring constants.  
𝜀(𝑡) =
𝑎1
𝐸2
𝑡 ∙ 𝑢(𝑡) +  𝑎1
𝜂1
(𝐸2)2
𝑢(𝑡) − 𝑎1
𝜂1
(𝐸2)2
𝑒
−𝐸2𝐸1
𝜂1(𝐸2+𝐸1)
𝑡
                                       (2) 
Because force and displacement data was collected on each participant using the HeartSMART 
system, the data can be plugged into equation 2 to solve for the three constants, η1, E1 and E2.   
4.2 Hypothesis for the Classification of Edema 
 The hypothesis is that in determining the values of η1, E1 and E2 for each participant and 
 
Figure 10. Viscoelastic models for soft tissue mechanics [Adapted from 41] 
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grouping the values according to the level of edema, a classification system can be created and 
used to predict the level of edema of future participants. To clarify, an analogy for color 
determination is used. Color in programming languages is represented by a red, green and blue 
component. The output color is a combination of these three colors, with values commonly 
ranging from 0 to 255 for each component. In this study, color is comparable to the edema score 
while the red, green, and blue components are comparable to η1, E1 and E2. The first step is to 
determine what numerical values of η1, E1 and E2 correspond to each edema level. Because the 
values will vary from patient to patient, an average and range for each constant must be 
established for each edema level. The next step is to conduct a blind study by testing another 
sample of participants with the clinician assigned edema score not revealed until the end of the 
study. Applying equation 2 to the collected data and determining the values of η1, E1 and E2 for 
each participant, the edema score can be predicted. By comparing the predicted scores and the 
clinician assigned scores, the process can be validated.  
 
  
  
 
 
CHAPTER 5: CLINICAL DATA COLLECTION 
5.1 Subject Participation 
During clinical data collection, the HeartSMART system was implemented to collect 
measurements from the lower legs of subjects. Subjects were recruited to collect data on the 
HeartSMART system prototype. In the process of selecting subjects, the NIH Outreach 
Notebook for the Inclusion, Recruitment and Retention of Women and Minority Subjects in 
Clinical Research (October 2001) and Increasing Diversity in Clinical Research (The Endocrine 
Society, 2007) was employed. Healthy subjects on and off the East Carolina University campus 
were notified of the study. Students 
attending East Carolina University 
were not allowed to participate in the 
study; only faculty and staff on campus 
were contacted. In order to collect data 
on HF patients, Dr. John Cahill of the 
East Carolina University Heart 
Institute (ECHI) discussed the study 
with his patients to determine if they were interested in participating. Heart failure subjects were 
required to meet the following criteria: alert, oriented, and understood the English language; 40 
years or older; understood and were capable of providing consent; diagnosed with heart failure 
and classified using the New York Heart Association (NYHA) functional class (I, II, III, or IV; 
as documented by the cardiologist) and community dwelling. In order to collect data on geriatric 
patients, Dr. Candace Harrington of the Monk Geriatric Center discussed the study with her 
patients to determine if they were interested in participating. Geriatric subjects were required to 
 
Figure 11:  Setup for subject testing 
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meet the following criteria: alert, oriented, and understood the English language; 40 years or 
older; understood and were capable of providing consent. Heart failure and geriatric subjects 
could not have the following conditions: cognitive impairment; impaired hearing as documented 
in the medical record or by observation and documented history of chronic mental illness. After 
interest was expressed from either a healthy subject, HF subject, or geriatric subject, the subject 
will met with a research assistant to sign up for the study. Figure 11 illustrates the setup for 
patient testing.   
Sample size initially depended on the number of consenting subjects. Sample size was 
based on subject volume accessibility in the clinic and is restricted by budget size. The total 
number of subjects tested was 30. Clinician edema scores were collected in addition to other 
demographic information to that the sample pool consisted of a diverse group of individuals. 
Table 3 in Chapter 5.3 illustrates the diversity in the sample population.  
5.2 Implemented Subject Protocol 
 Testing begins with the tester collecting the subject’s forehead and peripheral skin 
temperature. Next, the subject steps on the scale and his/her weight is recorded. Then the subject 
places his/her leg into the device. The tester pulls on the indentation lever, causing the 
indentation device to press into the subject’s skin at an approximate force of 4 lb. At this force, 
the skin indents to a certain depth. Measurements are taken on the lower anterior and lateral parts 
of both legs. The indentation procedure is performed a minimum of 3 times at each position. 
Displacement (mm) and force (lb) measurements are recorded and stored with LabView and 
Microsoft Excel, respectively. The testing protocol has been approved by the ECU UMCIRB. A 
detailed, step-by-step procedure is explained in Appendix D. The most recent approved 
amendment to the IRB is provided in Appendix E. 
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5.3 Summary of Subject Data 
A total of 30 subjects participated in the edema study. A variety of category data were 
collected on each participant to potentially be used in the data analyses. Clinician edema score, 
age, gender, race, and weight are displayed in Table 3. Any information blocked out in Table 3 
was a result of no data collection on the category at the particular point in time during the study.  
Table 3 shows an equal distribution of male and female participants with both Caucasian and 
Table 3. Subject data 
Subject 
Clinician 
Edema 
Score 
Age Gender Race 
Weight 
(kg) 
Weight 
(lb) 
Data Breakdown 
  
No. of 
Participants 
% of 
Participants 
Average 
Age 
Std 
Dev 
Age 
P17 0 53 M   147.4 325.8 
6 29% 72 14.40 
P18 0 66 M   91.1 201.3 
P20 0 88 F C 72.2 159.6 
P21 0 90 F C 48.6 107.4 
P22 0 66 F AA 126 278.5 
P23 0 67 M AA 84.8 187.4 
                      
P2 1 69 M   101.1 223.4 
6 29% 61 14.11 
P6 1 40 M   130 287.3 
P8 1 77 M   81.5 180.1 
P10 1 63 F   94 207.7 
P11 1 47 F   95.8 211.7 
P12 1 67 M   93.4 206.4 
                      
P5 2 64 M   120.3 265.9 
5 24% 61 13.43 
P7 2 61 M   92.4 204.2 
P13 2 39 F   122 269.6 
P14 2 63 F   116.6 257.7 
P15 2 76 F   95 210.0 
                      
P1 3 76 F   97 214.4 
4 19% 79 14.68 
P3 3 60 M   92.4 204.2 
P9 3 88 M   61.6 136.1 
P19 3 93 M C 77.1 170.4 
Total 21 70% 67 15.15 
                      
H1 NA   M C 94 207.7 
  
H2 NA   F C 78.4 173.3 
H3 NA   M C 96.2 212.6 
H4 NA   F C 64.4 142.3 
H5 NA 45 M AA 131.2 290.0 
H6 NA 42 F AA 152.3 336.6 
H7 NA 51 F C 71.1 157.1 
H8 NA 49 F C 108.4 239.6 
H9 NA 60 F C 57.2 126.4 
Total 9 30% 49 6.88 
*M: Male; F: Female; C: Caucasian; AA: African American 
*NA: All healthy subjects exhibited no edema 
*No data could be collected on subjects P4 and P16 because the force sensor was not working 
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African American representation. The number of participants in each edema level category (level 
0, level 1+, level 2+, and level 3+) ranged from 4 to 6 with average ages in the 60s and 70s. 
There were a total of 9 healthy subjects (control) with an average age of 49.  
 Although other data were collected, including surface skin temperatures and force and 
displacement measurements, these data are not included Table 3. An analysis of the surface skin 
temperature correlation to edema level is shown in Chapter 6.1 in Figure 12. Appendix F 
provides Excel worksheets of force and displacement data with calculations of E1, E2, and η1 as 
pertinent to the SLS model. Table 4 in Chapter 6.2 provides an overall summary of these 
calculated values. 
  
  
 
 
CHAPTER 6:  RESULTS 
6.1 Data Analyses 
  The HeartSMART system was developed to calculate the level of peripheral edema via 
four factors: the depth (displacement) of the skin, the force exerted on the skin, the surface 
temperature of the skin, and body weight. To determine the extent of the relative contribution of 
each, this section presents the analyses of the data. Refer to Appendix D for participant testing 
protocol. 
Figure 12 exhibits the number of participants in each weight category per edema level. The 
significance of this figure is to illustrate that each edema level consisted of participants with 
varying weight levels. One of the events that occurred during the study that is not indicated in 
Table 3 is that participant P1 and P15 are the same person. It appears that by merely losing weight 
(4.4 lb), the patient’s edema level changed from a 3+ to 2+.  
 
Figure 12. Weight distribution of participants within each edema level 
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Figure 13 illustrates the surface skin temperatures where the force and displacement 
measurements were taken. On average, more of the participants in the healthy and level 2+ 
groups had warmer skin temperatures compared to the other groups. In fact, the median for 
healthy and level 2+ were similar (95.7°F and 96.2°F, respectively). Although the median for 
level 0 (94.95°F) was comparable to healthy and level 2+, the range of temperatures had greater 
variance. When considering level 1 and level 3, the median dropped (89.7°F and 86.2°F), 
respectively) and the range increased. From this plot, one could deduce that on average, 
participants with edema level 3+ will have cooler surface skin temperatures compared to lower 
levels of edema. It is interesting to note that in a 2016 study conducted by Oya et al. there was 
evidence of low temperature skin surfaces in areas exhibiting subcutaneous edema [43]. 
Table 4 provides a summary of the calculated averages and standard deviations for the 
slope of the force curve and η1, E1 and E2 at each testing location on the leg for the corresponding 
edema level. To better visualize these data, Figures 14-28 contain bar charts. 
 
Figure 13. Surface skin temperatures within each edema level   
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Table 4. Summary of force slope, E1, E2, and η1 values  
Location: Front of Left Leg 
Control (Healthy Subjects; No Edema) 
  ΔF/ΔT E1 E2 η1 
Total Averages 2.0 2,108,338 52.3 20.1 
Total Standard Deviations 0.5 869,414 6.9 3.0 
Edema Level: 0 
  ΔF/ΔT E1 E2 η1 
Total Averages 3.5 3,577,110 68.9 47.0 
Total Standard Deviations 1.0 4,475,202 54.9 15.9 
Edema Level: 1+ 
  ΔF/ΔT E1 E2 η1 
Total Averages 2.4 3,755,309 26.9 8.9 
Total Standard Deviations 1.2 6,714,545 11.2 2.9 
Edema Level: 2+ 
  ΔF/ΔT E1 E2 η1 
Total Averages 3.1 1,575,836 18.3 9.2 
Total Standard Deviations 1.7 1,232,253 7.2 5.8 
Edema Level: 3+ 
  ΔF/ΔT E1 E2 η1 
Total Averages 3.0 1,551,191 19.4 9.9 
Total Standard Deviations 1.4 1,946,346 5.8 5.6 
       
Location: Side of Left Leg 
Control (Healthy Subjects; No Edema) 
  ΔF/ΔT E1 E2 η1 
Total Averages 2.8 2,084,255 14.3 6.7 
Total Standard Deviations 1.1 809,173 2.5 3.3 
Edema Level: 0 
  ΔF/ΔT E1 E2 η1 
Total Averages 2.7 3,032,282 19.6 7.6 
Total Standard Deviations 0.7 3,229,144 4.9 3.0 
Edema Level: 1+ 
  ΔF/ΔT E1 E2 η1 
Total Averages 2.6 6,397,778 43.4 20.3 
Total Standard Deviations 0.9 5,255,159 13.0 14.1 
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Edema Level: 2+ 
  ΔF/ΔT E1 E2 η1 
Total Averages 3.0 1,518,882 18.7 11.4 
Total Standard Deviations 2.0 1,496,963 7.2 8.1 
Edema Level: 3+ 
  ΔF/ΔT E1 E2 η1 
Total Averages 2.4 1,957,078 10.1 7.2 
Total Standard Deviations 1.3 2,280,181 4.8 7.0 
  
Location: Front of Right Leg 
Control (Healthy Subjects; No Edema) 
  ΔF/ΔT E1 E2 η1 
Total Averages 3.1 2,625,398 63.3 18.6 
Total Standard Deviations 1.4 2,090,086 47.0 12.9 
Edema Level: 0 
  ΔF/ΔT E1 E2 η1 
Total Averages 3.3 1,213,612 24.6 9.7 
Total Standard Deviations 1.2 1,248,658 11.6 8.5 
Edema Level: 1+ 
  ΔF/ΔT E1 E2 η1 
Total Averages 2.2 1,391,898 16.9 7.1 
Total Standard Deviations 0.9 1,211,250 6.0 5.0 
Edema Level: 2+ 
  ΔF/ΔT E1 E2 η1 
Total Averages 5.4 5,662,163 28.0 16.4 
Total Standard Deviations 6.3 4,421,763 13.0 7.9 
Edema Level: 3+ 
  ΔF/ΔT E1 E2 η1 
Total Averages 2.7 1,941,973 30.3 10.3 
Total Standard Deviations 1.5 2,604,442 5.4 5.4 
  
Location: Side of Right Leg 
Control (Healthy Subjects; No Edema) 
  ΔF/ΔT E1 E2 η1 
Total Averages 3.2 3,784,776 45.6 24.6 
Total Standard Deviations 1.3 82,218 8.8 8.8 
Edema Level: 0 
  ΔF/ΔT E1 E2 η1 
Total Averages 2.6 6,357,948 30.8 9.5 
Total Standard Deviations 1.0 6,322,928 15.1 6.0 
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Edema Level: 1+ 
  ΔF/ΔT E1 E2 η1 
Total Averages 2.8 1,234,951 18.2 16.4 
Total Standard Deviations 1.2 1,188,190 9.0 2.6 
Edema Level: 2+ 
  ΔF/ΔT E1 E2 η1 
Total Averages 4.7 1,414,067 28.8 9.2 
Total Standard Deviations 2.5 2,605,600 10.6 8.6 
Edema Level: 3+ 
  ΔF/ΔT E1 E2 η1 
Total Averages 3.0 2,202,599 15.2 9.4 
Total Standard Deviations 2.8 1,953,846 9.4 5.8 
 
 
Figures 14 -25 represent the data summarized in Table 4. Figures 14-17 show the average 
η1 value for each of  the four leg locations for each group of edema level participants. Figures 
18-21 show the average E1 value for each of  the four leg locations for each group of edema level 
participants. Figures 22-25 show the average E2 value for each of  the four leg locations for each 
group of edema level participants. The data are displayed in the following order on each graph: 
Control (Healthy), Level 0, Level 1+, Level 2+, and Level 3+. Note that N represents the number 
of runs, where a run is defined as each time the indentation device is pushed into the participant’s 
leg and then released.  
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Figure 14. η1 for the front location of the left leg 
 
Figure 15. η1 for the side location of the left leg 
 
Figure 16. η1 for the front location of the right leg 
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Figure 17. η1 for the side location of the right leg 
After a thorough review of all the force and displacement data collected, the front left 
side of the leg provided the most reliable data and had the largest sample size when compared to 
the other three locations. Therefore, the front left location will be used when establishing the 
classification system for a standardized edema score. Figure 14 shows that there is a difference in 
η1 values when comparing tissue with no edema versus tissue with edema. After performing t-
test analyses and Wilcoxon statistical tests, there was a statistically significant difference 
between Control/Level 0 and Levels1,2,3 and between Level 0 and Levels 1,2,3 for the front left 
location (p-value equal to 0.01 and 0.02, respectively). There was a statistically significant 
difference between Control/Level 0 and Levels1,2,3 and between Level 0 and Levels 1,2,3 for 
the side left location (p-value equal to 0.01 and 0.02, respectively). There was not a statistically 
significant difference for the other two locations.  
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 Figure 18. E1 for the front location of the left leg 
  
Figure 19. E1 for the side location of the left leg 
 
Figure 20. E1 for the front location of the right leg 
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Figure 21. E1 for the side location of the right leg 
Figures 18-21 illustrate that the values of E1 are significantly large, with the smallest 
value approximately 2,000,000 lb/mm, indicating that the spring is extremely stiff for tissue with 
no edema and edematous tissue. After performing t-test analyses and Wilcoxon statistical tests, 
there was not a statistically significant difference between Control/Level 0 and Levels1,2,3 or 
between Level 0 and Levels 1,2,3 for all locations.
 
Figure 22. E2 for the front location of the left leg 
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Figure 23. E2 for the side location of the left leg  
 
Figure 24. E2 for the front location of the right leg  
 
Figure 25. E2 for the side location of the right leg 
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Figure 22 shows that there is a difference in E2 values when comparing tissue with no 
edema versus tissue with edema for the front left and side left locations. After performing t-test 
analyses and Wilcoxon statistical tests, there was a statistically significant difference between 
Control/Level 0 and Levels1,2,3  for the front left location (p-value equal to 0.04) but not a 
statistically significant difference between Level 0 and Levels 1,2,3 for the front left location. 
There was a statistically significant difference between Control/Level 0 and Levels1,2,3 and 
between Level 0 and Levels 1,2,3 for the side left location (p-value equal to 0.01 and 0.04, 
respectively). There was not a statistically significant difference for the other two locations (front 
right and side right). 
6.2 Edema Rankings 
Due to the fact that the front left location provided the most reliable data, the η1 and E2 
values from this location will be used for the classification system. This classification 
distinguishes between edematous tissue and tissue without edema. Because the values of E1 were 
so large, this spring can be removed from the model and replaced with a rigid bar. The 
configuration of the model then changes from the SLS model to the Kevin-Voight model, as 
previously shown in Figure 10.  
 
 
 
  
  
 
 
CHAPTER 7:  DISCUSSION 
7.1 Rationale and Application 
 Clinicians and researchers investigating management of HF voice interest in tools and 
models that assist with improved diagnostic capability, and thus advancements in treatment of 
associated health issues. The importance of self-care management behaviors to overall health are 
becoming increasingly known. For these reasons, the potential of the HeartSMART system 
deserves thoughtfully designed investigations. This thesis project focused on design of an in-
home monitoring system that can objectively measure peripheral edema. Furthermore, the 
system incorporates a standard linear solid (SLS) analysis based on a viscoelastic tissue model. 
In this study, we have recorded force and displacement measurements from participants with 
varying levels of edema then fit this data to a SLS model in order to establish edematous tissue 
properties. Fundamental to this project is the knowledge that human tissues exhibit significant 
viscoelastic effects. These effects are measurable. Phenomena in viscoelastic materials that can 
be measured are as follows: (1) creep, in which strain increases with time if stress is constant; (2) 
relaxation, in which stress decreases with time if 
strain is constant; and (3) effective stiffness, 
which relies on application rate of the load [42]. 
An example of the phenomenon of creep, as 
shown in Figure 29, is a placing a 1,000 lb 
security safe in the attic. When the stress of the 
safe is first applied to the floor, the floor will 
displace a small amount. Over time, the floor 
will displace more, even though the weight of 
 
Figure 26. Creep and recovery for stress (σ) 
and strain (ε) versus time curves [42] 
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the safe remains the same.  
In this study, stress could not be held constant, and therefore manipulations to the model 
were necessary. Using the SLS model, the constants η1, E1, and E2 were calculated. Findings 
showed significantly high values E1, indicating that a relatively large amount of force was 
necessary to cause little displacement.  
7.2 Recommended Improvements 
Through clinical testing, we discovered improvement opportunities to the device design 
to obtain more reliable data and make the device more user friendly in a clinical and home 
setting, such as: 
• Allow patient to sit instead of stand during testing 
• Redesign indentation lever so participants will not use it as a means to support themselves 
during body weight measurements; also make the lever automated   
• Affix a temperature sensor onto the device instead of using a thermometer 
• Move force sensor inside displacement housing to prevent damage to the sensor 
• Secure the device on a wall instead of using a standalone to increase  stability and enhance 
ease of use 
7.3 Future Direction 
Further study is necessary to elaborate on the device deign and algorithm to determine a 
deeper meaning of the parameters. Conducting a breadth study of a minimum of a hundred participants 
across many different edematous tissue types could demonstrate whether the model can predict 
level of edema in an objective manner. In addition, retesting the same participants would provide 
greater insight on measurement consistency.  
The next step is to use the data from the analyses to predict the edema score for another 
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sample of participants. By comparing the predicted scores and the clinician assigned scores, the 
process can be validated.  
 Based on the design of the system, the skin rebound time could not be captured. Future 
prototypes are under discussion that would include sensors that could measure this parameter.  
  
  
 
 
CHAPTER 8: CONCLUSION 
The HeartSMART system is a vital tool that can be used by health care professionals to 
monitor heart failure progression and by patients to improve their self-management skills. 
Continual use of this system will help individuals recognize how significant weight control and 
fluid monitoring is to their overall health and prevention of worsening conditions. The goal of 
collecting force and displacement data from the sensors and using these measurements to derive 
the constants η1, E1 and E2 for each level of edema was met.  
The importance of implementing the tissue model cannot be overemphasized despite 
some of the unexplainable findings. Increasing the sample size, repeating the study on the same 
group of participants, and improving the system design as suggested in Chapter 7.2 all have the 
potential to achieve a higher modeling accuracy. A more informed focus, per findings from this 
study, is suggested to take into consideration more subtle changes in tissue properties. 
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APPENDIX A: SENSOR HOUSING DESIGN SKETCH 
Original work by Dr. Stephanie George 
  
  
  
 
 
APPENDIX B: FOAM PROTOCOL 
Materials Quantity 
Airtex high-density foam: 1 inch x 15 inch x 17 inch 1 
Food Lion large rectangle plastic storage container: 76 fluid ounces 3 
Ziploc freezer bag: 1 quart 5 
Stanley 1-blade utility knife 1 
Crisco pure vegetable oil: 1 gallon 1 
Hefty EZ Foil all-purpose pan: 13.25 inch x 9.625 inch x 2.75 inch 1 
PVC cyclindrical pipe: 3 inch diameter 1 
Quikrete concrete mix: 50 pound bag 1 
Hacksaw 1 
Durabuilt measuring tape: 12 feet 1 
Sharpie pen 1 
Hot glue gun with glue 1 
Sunbeam household iron 1 
 
Lower Leg Model Design 
1. Cut a 3 inch diameter PVC pipe to a length of 18 inches with a hacksaw.  
2. Mix approximately 25 pounds of concrete with water per the manufacturer’s instructions 
and fill the EZ foil pan with the mixture.  
3. Immediately place the PVC pipe upright in the center of the pan and hold until the 
mixture sets (approximately 20 minutes). 
4. Allow mixture to dry overnight.  
Foam Model Design 
1. Cut six 4 inch x 4 inch pieces of foam using the box cutter. Using the Sharpie, label the 
samples on the top and bottom “1” through “5.” Label the sixth sample as “E” for extra. 
2. Set sample 4 to the side. Relabel as “1.00 inch.” 
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3. Measure 0.25 inches deep on sample 1 and mark around each edge with the Sharpie. Use 
box cutter to cut the 1 inch thick sample to 0.25 inches thick. Dispose of the leftover 0.75 
inch thick piece. Relabel sample as “0.25 inches.” 
4. Measure 0.50 inches deep on sample 2 and mark around each edge with the Sharpie. Use 
box cutter to cut the 1 inch thick sample to 0.50 inches thick. Dispose of the leftover 0.50 
inch thick piece. Relabel sample as “0.50 inches.” 
5. Measure 0.75 inches deep on sample 3 and mark around each edge with the Sharpie. Use 
box cutter to cut the 1 inch thick sample to 0.25 inches thick. Dispose of the leftover 0.25 
inch thick piece. Relabel sample as “0.75 inches.” 
6. Measure 0.25 inches deep on sample E and mark around each edge with the Sharpie. Use 
box cutter to cut the 1 inch thick sample to 0.25 inches thick. Dispose of the leftover 0.75 
inch thick piece. Hot glue this 0.25 inch sample to sample 5 and relabel as “1.25 inches.” 
7. Place the “0.25 inch” sample and “0.50 inch” sample in one large rectangle container. Fill 
the container with 38 fluid ounces of vegetable oil and cover with the lid. Allow the 
samples to soak in the oil overnight.  
8. Place the “0.75 inch” sample and “1.00 inch” sample in one large rectangle container. Fill 
the container with 38 fluid ounces of vegetable oil and cover with the lid. Allow the 
samples to soak in the oil overnight.  
9. Place the “1.25 inch” sample in one large rectangle container. Fill the container with 38 
fluid ounces of vegetable oil and cover with the lid. Allow the sample to soak in the oil 
overnight.  
10. Remove each piece of foam from the oil filled containers and allow 30 seconds to drain 
out excess oil. 
11. Place each sample individually in a Ziploc bag. Cut each bag to allow 0.125 inches 
around each edge of the foam. Seal around all four edges of each bag with an iron.  
12. Lay sealed foam bags flat on a table until testing with the lower leg model and 
HeartSMART system commences.  
Device Setup 
1. Run the LabView Force and Displacement Program (LFDP) on the university laptop. 
2. Plug in the NI Elvis II+ circuit board into the power supply. Connect the laptop to the 
circuit board with the USB cable. Turn on the circuit board. 
3. Place the base of the HeartSMART system on the floor. Check the force sensor and 
displacement sensor connections to the circuit board by running the LFDP. Troubleshoot 
if necessary. 
4. Close and restart the LFDP in preparation for foam testing.  
Foam Testing 
1. Position the lower leg model (as described above) in the shin guard of the HeartSMART 
system.  
2. Record the foam thickness of sample 1 (0.25 inch) in the LFDP. 
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3. Take the “0.25 inch” foam sample and place it between the shin guard and lower leg 
model. Ensure sample is positioned such that the indentation device will make contact 
with it. 
4. Immediately run the LVDP to prevent loss of oil from the center of the sample. 
5. Push on the lever arm and apply a maximum force between 4 and 5 pounds. Hold at this 
force for 1 to 3 seconds. Release the lever arm.  
6. Repeat step 5 two more times. Stop the LFDP. 
*Note: Displacement (mm) and force (lb) measurements for each of the three runs are 
automatically recorded and stored with LabView and Microsoft Excel software, respectively. 
Each time the LFDP is started and stopped, a new excel file is created. 
7. Remove foam sample from in between shin guard and lower leg model. 
8. Record the foam thickness of sample 2 (0.50 inch) in the LFDP. 
9. Take the “0.50 inch” foam sample and place it between the shin guard and lower leg 
model. Ensure sample is positioned such that the indentation device will make contact 
with it. 
10. Immediately run the LVDP to prevent loss of oil from the center of the sample. 
11. Push on the lever arm and apply a maximum force between 4 and 5 pounds. Hold at this 
force for 1 to 3 seconds. Release the lever arm.  
12. Repeat step 11 two more times. Stop the LFDP. 
13. Remove foam sample from in between shin guard and lower leg model. 
14. Record the foam thickness of sample 3 (0.75 inch) in the LFDP. 
15. Take the “0.75 inch” foam sample and place it between the shin guard and lower leg 
model. Ensure sample is positioned such that the indentation device will make contact 
with it. 
16. Immediately run the LVDP to prevent loss of oil from the center of the sample. 
17. Push on the lever arm and apply a maximum force between 4 and 5 pounds. Hold at this 
force for 1 to 3 seconds. Release the lever arm.  
18. Repeat step 17 two more times. Stop the LFDP. 
19. Remove foam sample from in between shin guard and lower leg model. 
20. Record the foam thickness of sample 4 (1.00 inch) in the LFDP. 
21. Take the “1.00 inch” foam sample and place it between the shin guard and lower leg 
model. Ensure sample is positioned such that the indentation device will make contact 
with it. 
22. Immediately run the LVDP to prevent loss of oil from the center of the sample. 
23. Push on the lever arm and apply a maximum force between 4 and 5 pounds. Hold at this 
force for 1 to 3 seconds. Release the lever arm.  
24. Repeat step 23 two more times. Stop the LFDP. 
25. Remove foam sample from in between shin guard and lower leg model. 
26. Record the foam thickness of sample 5 (1.25 inch) in the LFDP. 
27. Take the “1.25 inch” foam sample and place it between the shin guard and lower leg 
model. Ensure sample is positioned such that the indentation device will make contact 
with it. 
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28. Immediately run the LVDP to prevent loss of oil from the center of the sample. 
29. Push on the lever arm and apply a maximum force between 4 and 5 pounds. Hold at this 
force for 1 to 3 seconds. Release the lever arm.  
30. Repeat step 29 two more times. Stop the LFDP. 
31. Remove foam sample from in between shin guard and lower leg model. 
Post Testing 
1. Create a new folder labeled with the date of testing. 
2. Move the five excel files (0.25 inch, 0.50 inch, 0.75 inch, 1.00 inch, and 1.25 inch) to the 
folder for future data retrieval and analysis. 
 
 
  
  
 
APPENDIX C:  SLS FINAL EQUATION DERIVATION 
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APPENDIX D: DEVICE TESTING PROTOCOL 
Device Setup 
5. Run the LabView Force and Displacement Program (LFDP) on the university laptop. 
6. Plug in the NI Elvis II+ circuit board into the power supply. Connect the laptop to the 
circuit board with the USB cable. Turn on the circuit board. 
7. Place the base of the HeartSMART system on the floor. Check the force sensor and 
displacement sensor connections to the circuit board by running the LFDP. Troubleshoot 
if necessary. 
8. Close and restart the LFDP in preparation for participant testing.  
Participant Testing 
1. Greet and introduce yourself to the participant, who is either a healthy subject or patient 
(Patients were brought to the testing room by the healthcare provider. Healthy subjects 
were informed of the study either through a university email or an announcement at the 
Monk clinic). 
2. Once participant is seated, explain step by step all pages of the “Informed Consent to 
Participate in Research” and “UMCIRB HIPAA Privacy Authorization” forms. Note: For 
healthy subjects, only the “Informed Consent to Participate in Research” form is required. 
3. Ask participant if he/she has any questions and answer accordingly. Give the participant 
the appropriate forms to initial and sign.  
4. Verify participant has initialed at the bottom of every page of the informed consent form. 
Verify participant has printed and signed his/her name and dated the last page of the 
informed consent. Verify patient has printed and signed his/her name and dated the last 
page of the HIPAA form. 
5. Assign participant a number. Note: All future references to the participant from this point 
on will only be associated with the assigned number and not the name in order to protect 
participant identity. 
6. Collect the participant’s forehead temperature with the thermometer. Record the 
temperature in the Participant Data excel file.  
7. Enter the participant’s assigned number in the LFDP. 
8. While seated, have the participant remove his/her shoes. 
9. Collect the participant’s weight by having him/her stand on the Withings scale. Record 
the weight in the LFDP. 
10. Allow participant to sit on a roller chair. Collect the skin temperature of the outside lower 
portion of the participant’s left leg. Record the temperature in the LFDP. 
11. Place the outside lower portion of the participant’s left leg in the shin guard. Verify the 
participant’s leg is aligned correctly with the indentation device so that contact with the 
skin will occur. Verify the participant is resting his/her leg in the shin guard and is not 
pushing against the shin guard.  
12. Record the testing location (side of left leg) in the LFDP. 
13. Run the LVDP.  
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14. Push on the lever arm and apply a maximum force between 4 and 5 pounds. Hold at this 
force for 1 to 3 seconds. Release the lever arm.  
15. Repeat step 14 two more times. Stop the LFDP.  
*Note: Displacement (mm) and force (lb) measurements for each of the three runs are 
automatically recorded and stored with LabView and Microsoft Excel software, respectively. 
Each time the LFDP is started and stopped, a new excel file is created. 
16. Allow participant to remove his/her leg from the shin guard. 
17. Collect the skin temperature of the front lower portion of the participant’s left leg. Record 
the temperature in the LFDP. 
18. Place the front lower portion of the participant’s left leg in the shin guard. Verify the 
participant’s leg is aligned correctly with the indentation device so that contact with the 
skin will occur. Verify the participant is resting his/her leg in the shin guard and is not 
pushing against the shin guard.  
19. Record the testing location (front of left leg) in the LFDP. 
20. Run the LVDP.  
21. Push on the lever arm and apply a maximum force between 4 and 5 pounds. Hold at this 
force for 1 to 3 seconds. Release the lever arm.  
22. Repeat step 21 two more times. Stop the LFDP. 
23. Allow participant to remove his/her leg from the shin guard. 
24. Collect the skin temperature of the front lower portion of the participant’s right leg. 
Record the temperature in the LFDP. 
25. Place the front lower portion of the participant’s right leg in the shin guard. Verify the 
participant’s leg is aligned correctly with the indentation device so that contact with the 
skin will occur. Verify the participant is resting his/her leg in the shin guard and is not 
pushing against the shin guard.  
26. Record the testing location (front of right leg) in the LFDP. 
27. Run the LVDP.  
28. Push on the lever arm and apply a maximum force between 4 and 5 pounds. Hold at this 
force for 1 to 3 seconds. Release the lever arm.  
29. Repeat step 28 two more times. Stop the LFDP. 
30. Allow participant to remove his/her leg from the shin guard. 
31. Collect the skin temperature of the outside lower portion of the participant’s right leg. 
Record the temperature in the LFDP. 
32. Place the outside lower portion of the participant’s right leg in the shin guard. Verify the 
participant’s leg is aligned correctly with the indentation device so that contact with the 
skin will occur. Verify the participant is resting his/her leg in the shin guard and is not 
pushing against the shin guard.  
33. Record the testing location (side of right leg) in the LFDP. 
34. Run the LVDP.  
35. Push on the lever arm and apply a maximum force between 4 and 5 pounds. Hold at this 
force for 1 to 3 seconds. Release the lever arm.  
36. Repeat step 35 two more times. Stop the LFDP. 
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37. Allow participant to remove his/her leg from the shin guard. 
38. Assist participant to a non-roller chair and have him/her put on his/her shoes. 
39. Thank the participant for his/her time and willingness to participate in the study. Escort 
participant to the location of their healthcare provider.  
40. While at the clinic, record the healthcare provider assigned edema score in the Participant 
Data.xls file. 
Post Testing 
3. Create a new folder labeled with the date of testing. 
4. Move the participant’s four excel files (side of left leg, front of left leg, front of right leg, 
side of right leg) to the folder for future data retrieval and analysis. 
5. For IRB purposes, take participant informed consent and HIPAA forms to committee 
member, Dr. Stephanie George, for secure storage. 
  
  
 
APPENDIX E: IRB AMMENDMENT APPROVAL 
 UMCIRB 14-0001: “Comparison of sensor and provider generated edema measurement” 
approval letter is shown below.  
 
  
  
 
APPENDIX F:  DATA SAMPLE FILES OF PATIENT 6 
   Raw data collected and analyses were performed on each participant. Figures 27-32 
illustrate such for patient 6.  
 
Figure 27. Sample worksheet of force and displacement raw data 
 
Figure 28. Example of displacement and force versus time curve 
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Figure 29. Example of one run of displacement and force versus time curve 
 
Figure 30. Sample worksheet of force slopes and displacement slopes 
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Figure 31. Sample worksheet of force versus displacement curves with slopes 
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Figure 32. Sample worksheet of SLS analysis  
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Figure 32 Continued. Sample worksheet of SLS analysis  
 
 
  
  
 
 
 
 
 
 
  
